84 related articles for article (PubMed ID: 9840933)
1. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
[TBL] [Abstract][Full Text] [Related]
2. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.
Saucier C; Papavasiliou V; Palazzo A; Naujokas MA; Kremer R; Park M
Oncogene; 2002 Mar; 21(12):1800-11. PubMed ID: 11896612
[TBL] [Abstract][Full Text] [Related]
3. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.
Bardelli A; Basile ML; Audero E; Giordano S; Wennström S; Ménard S; Comoglio PM; Ponzetto C
Oncogene; 1999 Feb; 18(5):1139-46. PubMed ID: 10022119
[TBL] [Abstract][Full Text] [Related]
4. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.
Fixman ED; Naujokas MA; Rodrigues GA; Moran MF; Park M
Oncogene; 1995 Jan; 10(2):237-49. PubMed ID: 7838524
[TBL] [Abstract][Full Text] [Related]
5. Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness.
Gual P; Giordano S; Anguissola S; Comoglio PM
Oncogene; 2001 Sep; 20(39):5493-502. PubMed ID: 11571647
[TBL] [Abstract][Full Text] [Related]
6. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
[TBL] [Abstract][Full Text] [Related]
7. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
Vigna E; Gramaglia D; Longati P; Bardelli A; Comoglio PM
Oncogene; 1999 Jul; 18(29):4275-81. PubMed ID: 10435641
[TBL] [Abstract][Full Text] [Related]
8. Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling.
Jeffers MF; Vande Woude GF
Oncogene; 1999 Sep; 18(36):5120-5. PubMed ID: 10490849
[TBL] [Abstract][Full Text] [Related]
9. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
10. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
11. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
Zhen Z; Giordano S; Longati P; Medico E; Campiglio M; Comoglio PM
Oncogene; 1994 Jun; 9(6):1691-7. PubMed ID: 8183564
[TBL] [Abstract][Full Text] [Related]
12. Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential.
Bardelli A; Longati P; Gramaglia D; Stella MC; Comoglio PM
Oncogene; 1997 Dec; 15(25):3103-11. PubMed ID: 9444958
[TBL] [Abstract][Full Text] [Related]
13. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
[TBL] [Abstract][Full Text] [Related]
14. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
Vempati S; Reindl C; Wolf U; Kern R; Petropoulos K; Naidu VM; Buske C; Hiddemann W; Kohl TM; Spiekermann K
Clin Cancer Res; 2008 Jul; 14(14):4437-45. PubMed ID: 18628457
[TBL] [Abstract][Full Text] [Related]
15. Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor.
Fournier E; Dubreuil P; Birnbaum D; Borg JP
Oncogene; 1995 Sep; 11(5):921-31. PubMed ID: 7675451
[TBL] [Abstract][Full Text] [Related]
16. Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.
Boerner JL; Danielsen AJ; Lovejoy CA; Wang Z; Juneja SC; Faupel-Badger JM; Darce JR; Maihle NJ
Oncogene; 2003 Oct; 22(43):6679-89. PubMed ID: 14555981
[TBL] [Abstract][Full Text] [Related]
17. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
[TBL] [Abstract][Full Text] [Related]
18. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis.
Bertotti A; Comoglio PM; Trusolino L
Cancer Res; 2005 Dec; 65(23):10674-9. PubMed ID: 16322210
[TBL] [Abstract][Full Text] [Related]
19. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
Zhang HT; O'Rourke DM; Zhao H; Murali R; Mikami Y; Davis JG; Greene MI; Qian X
Oncogene; 1998 Jun; 16(22):2835-42. PubMed ID: 9671404
[TBL] [Abstract][Full Text] [Related]
20. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation.
Du Villard JA; Wicker R; Crespo P; Russo D; Filetti S; Gutkind JS; Sarasin A; Suárez HG
Oncogene; 2000 Oct; 19(42):4896-905. PubMed ID: 11039907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
